Flt3 Ligand Augments Immune Responses to Spd1-Based DNA Vaccine Via Expansion of Cdc1s

Author:

Cai Zongyu,Qiao Yaru,Wuri Qimuge,Zhang Ke,Qu Xueli,Zhang Shiqi,Wu Hui,Wu Jiaxin,Wang Chu,Yu Xianghui,Kong Wei,Zhang Hai-Hong

Publisher

Elsevier BV

Reference37 articles.

1. Therapeutic cancer vaccines: advancements, challenges, and prospects;T Fan;Signal Transduct Target Ther,2023

2. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial;J W Youn;Lancet Oncol,2020

3. Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial;M L N Disis;JAMA Oncol,2023

4. DNA vaccines, electroporation and their applications in cancer treatment;S H Lee;Hum Vaccin Immunother,2015

5. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response;S P Shin;Mol Ther,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3